Nadroparin calcium

Nadroparin calcium

Systematic (IUPAC) name
(4S,6R)-6-[(2R,4R)-4,6-dihydroxy-5-(sulfonatoamino)-2-(sulfonatooxymethyl)oxan-3-yl]oxy-3,4-dihydroxy-5-sulfonatooxyoxane-2-carboxylate
Clinical data
Trade names	Fraxiparine, Fraxodi
AHFS/Drugs.com	International Drug Names
Legal status	AU: S4 (Prescription only) CA: ℞-only
Routes of administration	SC (except for haemodialysis)
Pharmacokinetic data
Bioavailability	89% (SC dose)
Biological half-life	3.7 hours (SC dose)
Excretion	clearance 21.4mL/min (+/- 7)
Identifiers
CAS Number	9041-08-1 Y
ATC code	B01AB06 (WHO)
DrugBank	DB08813 Y
KEGG	D07510 Y
Chemical data
Molecular mass	4300 g/mol
NY (what is this?)  (verify)

Nadroparin (trade name, Fraxiparine or Fraxodi) is an anticoagulant belonging to a class of drugs called low molecular weight heparins (LMWHs). Nadroparin was developed by sanofi-synthelabo.

Nadroparin is used in general and orthopedic surgery to prevent thromboembolic disorders (deep vein thrombosis and pulmonary embolism), and as treatment for deep vein thrombosis. It is also used to prevent clotting during hemodialysis, and for treatment of unstable angina and non-Q wave myocardial infarction.

For the treatment and prevention of DVT, the drug is administered as a subcutaneous injection (under the skin), usually around the stomach. Injections are given once or twice daily depending on the condition.

External links

• http://www.cancer.gov/Templates/drugdictionary.aspx?CdrID=483128
• http://www.mayoclinic.com/health/drug-information/DR600971